On Tuesday 20 February 2023 our PanACEA colleague Dr Norbert Heinrich presented the headline-results from the PanACEA SUDOCU study at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle – the largest and most important conference on HIV and related conditions such as tuberculosis. SUDOCU investigated safety and efficacy of varying doses of sutezolid – a compound in development for treatment of drug-resistant tuberculosis and treatment-shortening for drug-sensitive tuberculosis. The study was conducted at four PanACEA sites: National Institute for Medical Research (NIMR-MMRC), Ifakara Health Institute, Kilimanjaro Clinical Research Institute/Ki’bongoto Infectious Disease Hospital (all in Tanzania) and the Aurum Institute (South Africa). The study found that sutezolid added on top of a background regimen (bedaquiline, delamanid, moxifloxacin) was well tolerated over 12 weeks and improved the treatment efficacy modestly. The results will be instrumental for selection of dose in planned up-coming studies including sutezolid and give hope of replacing linezolid to generate a novel regimen with less toxicity but retained efficacy.
SUDOCU headline results presented at CROI
